Hydrolysate injections- 

a patent was filed in 2010 for cerebroprotein hydrolosate for treating brain injuries and neurodegenerative conditions affecting the brain.  After loss of neurons from brain injury, the injection of this hydrolysate can stimulate neurotrophic activity (growth of nerves) within 24 hours of receiving the hydrolysate.   This has the potential to reverse or mitigate the damage from cerebral injury.  Currently there is not enough scientific evidence to support routine use but this medication is probably to be accepted as standard therapy eventually.  Current Painbytes recommendation: neutral.    It is considered investigational by many insurers